tisagenlecleucel


( Last Updated : November 21, 2022)
Generic Name:
tisagenlecleucel
Project Status:
Pending
Therapeutic Area:
Relapsed or refractory follicular lymphoma
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Kymriah
Project Line:
Reimbursement Review
Project Number:
PG0306-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma

Details


Manufacturer Requested Reimbursement Criteria1:
‚ÄčTreatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
‚ÄčTreatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.